MediWound Ltd.: H.C. Wainwright recommends buying and sees 109% upside potential!
Reading Time: 3 minutes
MediWound Ltd. (MDWD) is a biotechnology company specializing in the development and commercialization of enzymatic, non-surgical therapies for tissue repair. The core business of the Israel-based company focuses on solutions for severe burns and chronic wounds, two areas with significant unmet medical needs. The main commercial product is NexoBrid, a biological preparation indicated for the enzymatic and selective removal of wound eschar in deep partial and full-thickness thermal burns. This therapy offers a non-surgical option in over 45 countries...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
